Department of Pathology, University of Chicago Medical Center, Chicago, IL, 60637, USA.
Department of Pathology, University of Chicago Medical Center, Chicago, IL, 60637, USA.
Hum Pathol. 2022 Mar;121:56-64. doi: 10.1016/j.humpath.2021.12.011. Epub 2022 Jan 10.
Limited tissue in biopsies of malignant bone lesions can preclude definitive subclassification, especially when cellular or matrix elements are sparse, absent, or confounding. It is uncertain whether immunohistochemistry for SOX9 (marker of chondrogenesis) and SATB2 (marker of osteoblastic differentiation) may be discriminatory tools toward osteosarcoma and chondrosarcoma. This study interrogated the preresection biopsies of a cohort of osteosarcoma and chondrosarcoma with SATB2 and SOX9 in tandem, to assess their value as diagnostic adjuncts as well as their concordance with the final resection diagnoses. SATB2 was expressed more frequently in osteosarcoma (46/53, 86%) than in chondrosarcoma (9/18, 50%); SOX9 was expressed in high frequencies in both osteosarcoma (52/53, 98%) and chondrosarcoma (17/18, 94%), and SATB2 and SOX9 were coexpressed in both osteosarcoma (46/53, 89%) and chondrosarcoma (8/18, 44%). There exists significant overlap in the expression of SATB2 and SOX9 in osteosarcoma and chondrosarcoma. These markers are not expressed in a distribution that is unique enough for application toward this particular diagnostic differential.
在恶性骨病变的活检组织中，组织有限可能排除明确的细分，尤其是当细胞或基质成分稀疏、缺失或混杂时。免疫组织化学检测 SOX9（软骨生成标志物）和 SATB2（成骨细胞分化标志物）是否可作为区分骨肉瘤和软骨肉瘤的工具尚不确定。本研究通过 SATB2 和 SOX9 的联合检测，对一组骨肉瘤和软骨肉瘤的术前活检进行了研究，以评估其作为诊断辅助工具的价值，以及与最终切除诊断的一致性。SATB2 在骨肉瘤（46/53，86%）中的表达频率高于软骨肉瘤（9/18，50%）；SOX9 在骨肉瘤（52/53，98%）和软骨肉瘤（17/18，94%）中均高频表达，SATB2 和 SOX9 在骨肉瘤（46/53，89%）和软骨肉瘤（8/18，44%）中均共表达。SATB2 和 SOX9 在骨肉瘤和软骨肉瘤中的表达存在显著重叠。这些标志物的表达没有足够独特的分布，无法应用于这种特定的诊断鉴别。
